VEGFR-2-IN-28

Cat. No.:	HY-147926
CAS No.:	2447597-39-7
Molecular Formula:	$C_{26}H_{17}N_7O_7$
Molecular Weight:	539.46
Target:	VEGFR; Apoptosis
Pathway:	Protein Tyrosine Kinase/RTK; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

VEGFR-2-IN-28 (compound 12c) is a potent VEGFR-2 inhibitor with IC_{50} value of 0.83 μM. VEGFR-2-IN-28 induces apoptosis and has anticancer activity[1].

IC_{50} & Target

VEGFR-2
0.83 μM (IC_{50})

In Vitro

VEGFR-2-IN-28 (compound 12c) (24 hours; MCF-7 cells) has anticancer activity with IC_{50} value of 16.50 μM[1].
VEGFR-2-IN-28 (compound 12c) (24 hours; MCF-7 cells) prompts pre-G1 apoptosis, cell growth cessation at G2/M phase and induces apoptosis via activation of caspase-3[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[1]

Cell Line:	MCF-7 cells
Concentration:	16.50 μM
Incubation Time:	24 hours
Result:	Induced apoptotic cells resulting in apoptosis percentage 28.41 %.

Cell Cycle Analysis[1]

Cell Line:	MCF-7 cells
Concentration:	16.50 μM
Incubation Time:	24 hours
Result:	Increased in the percentage of cells at pre-G1 phase and at G2/M phase to 28.41% and 46.05%, respectively.

Immunofluorescence[1]

Cell Line:	MCF-7 cells

Concentration:	16.50 μM
Incubation Time:	24 hours
Result:	Increased in the level of caspase-3.

REFERENCES

[1]. Dawood DH, et al. Synthesis and molecular docking study of new pyrazole derivatives as potent anti-breast cancer agents targeting VEGFR-2 kinase. Bioorg Chem. 2020 Aug;101:103916.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA